Table.
Demographic characteristics and clinical information of the study cohort
| Characteristics | Lactating (n=12) | Nonpregnant (n=20) | Pregnant (n=31) | P value |
|---|---|---|---|---|
| Age (y) | 33 (4) | 37 (8) | 34 (4) | .160 |
| Race (%) | ||||
| Asian | 0 (0) | 1 (5) | 1 (3) | .650 |
| Black or African American | 1 (8) | 2 (10) | 0 (0) | |
| Other | 0 (0) | 1 (5) | 1 (3) | |
| Unknown or not reported | 0 (0) | 1 (5) | 1 (3) | |
| White | 11 (92) | 15 (75) | 28 (90) | |
| Ethnicity (%) | ||||
| Hispanic | 0 (0) | 0 (0) | 2 (6) | .247 |
| Non-Hispanic | 12 (100) | 18 (90) | 29 (94) | |
| Unknown or not reported | 0 (0) | 2 (10) | 0 (0) | |
| Primary vaccine or vaccine series (%) | ||||
| Ad26.COV2.S | 1 (8) | 0 (0) | 6 (19) | .147 |
| mRNA-1273 | 5 (42) | 7 (35) | 14 (45) | |
| BNT162b2 | 6 (50) | 13 (65) | 11 (35) | |
| Primary vaccine series was received in pregnancy (%) | 11 (92) | — | 7 (23) | |
| Booster vaccine received (%) | ||||
| mRNA-1273 | 7 (58) | 7 (35) | 18 (58) | .251 |
| BNT162b2 | 5 (42) | 13 (65) | 13 (42) | |
| Time from completion of primary vaccine series to booster dose (d) | 246 (36) | 264 (26) | 241 (37) | .076 |
| Time from booster dose to sample collection (d) | 36 (17) | 45 (13) | 35 (13) | .033 |
| Gestational age at booster dose (completed wk)a | — | — | 28 (11) | |
| Time from booster dose to delivery (d)a | — | — | 61 (83) | |
| Previous COVID-19 infection (%) | 0 (0) | 1 (5) | 2 (6) | 1.0 |
Continuous data presented as mean (standard deviation), and categorical data are presented as number (percentage).
Atyeo. Antibody response to COVID-19 booster dose in pregnancy. Am J Obstet Gynecol 2023.
a
Pregnant cohort only.